{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:26:30Z","timestamp":1787685990935,"version":"build-2784847793"},"reference-count":206,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2307900"],"award-info":[{"award-number":["2023YFC2307900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2024YFC2309200"],"award-info":[{"award-number":["2024YFC2309200"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biosafety and Health"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bsheal.2026.06.002","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:14:27Z","timestamp":1780787667000},"page":"292-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Live-attenuated vaccines of human respiratory syncytial virus for infants and young children: Progress and prospects of an old yet promising platform"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2988-384X","authenticated-orcid":false,"given":"Jiemei","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanpeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bsheal.2026.06.002_b0005","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/thoraxjnl-2018-212212","article-title":"Respiratory syncytial virus (RSV): a scourge from infancy to old age","volume":"74","author":"Coultas","year":"2019","journal-title":"Thorax"},{"issue":"10340","key":"10.1016\/j.bsheal.2026.06.002_b0010","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bsheal.2026.06.002_b0015","doi-asserted-by":"crossref","unstructured":"E. Baraldi, G. Checcucci Lisi, C. Costantino, J.H. Heinrichs, P. Manzoni, M. Ricco, M. Roberts, N. Vassilouthis, RSV disease in infants and young children: Can we see a brighter future?, Hum. Vaccin. Immunother. 18 (4) (2022) 2079322, https:\/\/doi.org\/10.1080\/21645515.2022.2079322.","DOI":"10.1080\/21645515.2022.2079322"},{"issue":"6","key":"10.1016\/j.bsheal.2026.06.002_b0020","first-page":"543","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Am. J. Dis. Child."},{"issue":"10","key":"10.1016\/j.bsheal.2026.06.002_b0025","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/infdis\/jiad147","article-title":"Age-dependent risk of respiratory syncytial virus infection: a systematic review and hazard modeling from serological data","volume":"228","author":"Nakajo","year":"2023","journal-title":"J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.bsheal.2026.06.002_b0030","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1097\/INF.0b013e3181e9de24","article-title":"Virologically confirmed population-based burden of hospitalization caused by respiratory syncytial virus, adenovirus, and parainfluenza viruses in children in Hong Kong","volume":"29","author":"Chiu","year":"2010","journal-title":"Pediatr. Infect. Dis."},{"issue":"4","key":"10.1016\/j.bsheal.2026.06.002_b0035","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s15010-019-01287-5","article-title":"Respiratory syncytial virus contributes to more severe respiratory morbidity than influenza in children < 2 years during seasonal influenza peaks","volume":"47","author":"Amini","year":"2019","journal-title":"Infection"},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0040","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chom.2022.11.016","article-title":"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses","volume":"31","author":"Morens","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bsheal.2026.06.002_b0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.coviro.2017.03.012","article-title":"Vaccine development for respiratory syncytial virus","volume":"23","author":"Graham","year":"2017","journal-title":"Curr. Opin. Virol."},{"issue":"11","key":"10.1016\/j.bsheal.2026.06.002_b0050","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1128\/JVI.76.11.5654-5666.2002","article-title":"Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology","volume":"76","author":"Zhang","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.bsheal.2026.06.002_b0055","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM196207122670204","article-title":"Natural reinfection of adults by respiratory syncytial virus. possible relation to mild upper respiratory disease","volume":"267","author":"Johnson","year":"1962","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0060","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1203\/00006450-200209000-00009","article-title":"Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity","volume":"52","author":"Bont","year":"2002","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bsheal.2026.06.002_b0065","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fimmu.2014.00466","article-title":"Immunity to RSV in early-life","volume":"5","author":"Lambert","year":"2014","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.bsheal.2026.06.002_b0070","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1099\/jgv.0.000959","article-title":"ICTV Report Consortium, ICTV virus taxonomy profile","volume":"98","author":"Rima","year":"2017","journal-title":"Pneumoviridae, J. Gen. Virol."},{"issue":"8","key":"10.1016\/j.bsheal.2026.06.002_b0075","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s00705-016-2880-1","article-title":"Taxonomy of the order Mononegavirales: update 2016","volume":"161","author":"Afonso","year":"2016","journal-title":"Arch. Virol."},{"issue":"10","key":"10.1016\/j.bsheal.2026.06.002_b0080","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02357-16","article-title":"Broadly reactive anti-respiratory syncytial virus G antibodies from exposed individuals effectively inhibit infection of primary airway epithelial cells","volume":"91","author":"Cortjens","year":"2017","journal-title":"J. Virol."},{"issue":"309","key":"10.1016\/j.bsheal.2026.06.002_b0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0090","first-page":"281","article-title":"Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA): Isolation, properties and characterization","volume":"66","author":"Chanock","year":"1957","journal-title":"Am. J. Hyg."},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0095","first-page":"291","article-title":"Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children","volume":"66","author":"Chanock","year":"1957","journal-title":"Am. J. Hyg."},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1128\/CVI.00609-15","article-title":"Brief history and characterization of enhanced respiratory syncytial virus disease","volume":"23","author":"Acosta","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"issue":"4","key":"10.1016\/j.bsheal.2026.06.002_b0105","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.bsheal.2026.06.002_b0110","unstructured":"M. Schulson, For a pivotal vaccine: trial, error, and two young lives. https:\/\/undark.org\/2023\/10\/09\/rsv-vaccine-children-trials\/, 2023 (accessed 23 July 2025)."},{"issue":"10","key":"10.1016\/j.bsheal.2026.06.002_b0115","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1586\/erv.11.120","article-title":"Respiratory syncytial virus vaccine development","volume":"10","author":"Hurwitz","year":"2011","journal-title":"Expert Rev. Vaccines"},{"issue":"2","key":"10.1016\/j.bsheal.2026.06.002_b0120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1891\/NN-2023-0056","article-title":"Balanced on the biggest wave: Nirsevimab for newborns","volume":"43","author":"McPherson","year":"2024","journal-title":"Neonatal Netw."},{"key":"10.1016\/j.bsheal.2026.06.002_b0125","doi-asserted-by":"crossref","first-page":"107995","DOI":"10.1016\/j.cct.2025.107995","article-title":"Evaluation of a monoclonal antibody against respiratory syncytial virus, Clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials","volume":"157","author":"Sinha","year":"2025","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.bsheal.2026.06.002_b0130","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1186\/1471-2458-11-S3-S30","article-title":"An evaluation of the emerging interventions against respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children","volume":"11","author":"Nair","year":"2011","journal-title":"BMC Public Health"},{"issue":"7","key":"10.1016\/j.bsheal.2026.06.002_b0135","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S1473-3099(23)00062-2","article-title":"Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: An analysis of observational study sequencing data","volume":"23","author":"Wilkins","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bsheal.2026.06.002_b0140","article-title":"Strategies for active and passive pediatric RSV immunization","volume":"9","author":"Eichinger","year":"2021","journal-title":"Ther. Adv. Vaccines Immunother."},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0145","first-page":"14","article-title":"Progress in clinical research on pediatric respiratory syncytial virus vaccines [Chinese]","volume":"46","author":"Yu","year":"2026","journal-title":"Chin. J. Microbiol. Immunol."},{"key":"10.1016\/j.bsheal.2026.06.002_b0150","first-page":"65","article-title":"Breakthroughs and challenges in the development of human respiratory syncytial virus vaccines [Chinese]","volume":"12","author":"Yu","year":"2023","journal-title":"China Food Drug Admin."},{"issue":"8","key":"10.1016\/j.bsheal.2026.06.002_b0155","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.4049\/jimmunol.179.8.5415","article-title":"CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease","volume":"179","author":"Olson","year":"2007","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.bsheal.2026.06.002_b0160","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/vim.2009.0016","article-title":"Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease","volume":"22","author":"Stevens","year":"2009","journal-title":"Viral Immunol."},{"issue":"5","key":"10.1016\/j.bsheal.2026.06.002_b0165","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0264-410X(90)90253-I","article-title":"Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization","volume":"8","author":"Murphy","year":"1990","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.bsheal.2026.06.002_b0170","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0264-410X(92)90397-3","article-title":"Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia\u2013RSV recombinants or RSV","volume":"10","author":"Connors","year":"1992","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.bsheal.2026.06.002_b0175","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/jvi.66.12.7444-7451.1992","article-title":"Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB\/c mice is abrogated by depletion of CD4+ T cells","volume":"66","author":"Connors","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.bsheal.2026.06.002_b0180","doi-asserted-by":"crossref","unstructured":"K. Schneider-Ohrum, A. Snell Bennett, G.M. Rajani, L. Hostetler, S.K. Maynard, M. Lazzaro, L.I. Cheng, T. O'Day, C. Cayatte, CD4(+) T cells drive lung disease enhancement induced by immunization with suboptimal doses of respiratory syncytial virus fusion protein in the mouse model, J. Virol. 93 (15) (2019) e00695-19, https:\/\/doi.org\/10.1128\/JVI.00695-19.","DOI":"10.1128\/JVI.00695-19"},{"issue":"8","key":"10.1016\/j.bsheal.2026.06.002_b0185","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02180-16","article-title":"Immunization with low doses of recombinant postfusion or prefusion respiratory syncytial virus f primes for vaccine-enhanced disease in the cotton rat model independently of the presence of a th1-biasing (GLA-SE) or Th2-biasing (Alum) adjuvant","volume":"91","author":"Schneider-Ohrum","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.bsheal.2026.06.002_b0190","unstructured":"J. Cohen, \u2018Safety signal\u2019 in Moderna\u2019s RSV vaccine studies halts trials of other vaccines for childhood killer. https:\/\/www.science.org\/content\/article\/safety-signal-moderna-s-rsv-vaccine-studies-halts-trials-other-vaccines-childhood, 2024 (accessed 7 July 2025)."},{"key":"10.1016\/j.bsheal.2026.06.002_b0195","unstructured":"FDA, Considerations for Respiratory Syncytial Virus (RSV) vaccine safety in pediatric populations. https:\/\/www.fda.gov\/media\/184789\/download, 2024 (accessed 7 July 2025)."},{"issue":"2","key":"10.1016\/j.bsheal.2026.06.002_b0200","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/pathogens14020104","article-title":"Preventing RSV infection in children: current passive immunizations and vaccine development","volume":"14","author":"Babawale","year":"2025","journal-title":"Pathogens"},{"key":"10.1016\/j.bsheal.2026.06.002_b0205","article-title":"FDA pauses all infant RSV vaccine trials after rise in severe illnesses","volume":"387","author":"Mahase","year":"2024","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.bsheal.2026.06.002_b0210","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1086\/427813","article-title":"Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants","volume":"191","author":"Karron","year":"2005","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.bsheal.2026.06.002_b0215","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1086\/514138","article-title":"Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children","volume":"176","author":"Karron","year":"1997","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.bsheal.2026.06.002_b0220","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1086\/315859","article-title":"Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy","volume":"182","author":"Wright","year":"2000","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.bsheal.2026.06.002_b0225","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1086\/499600","article-title":"The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans","volume":"193","author":"Wright","year":"2006","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.bsheal.2026.06.002_b0230","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0022-3476(76)81044-X","article-title":"Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants","volume":"88","author":"Wright","year":"1976","journal-title":"J. Pediatr."},{"issue":"7","key":"10.1016\/j.bsheal.2026.06.002_b0235","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1203\/00006450-197407000-00001","article-title":"Attenuated respiratory syncytial virus vaccines in asthmatic children","volume":"8","author":"McIntosh","year":"1974","journal-title":"Pediatr. Res."},{"issue":"42","key":"10.1016\/j.bsheal.2026.06.002_b0240","doi-asserted-by":"crossref","first-page":"7372","DOI":"10.1016\/j.vaccine.2007.08.014","article-title":"The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines","volume":"25","author":"Wright","year":"2007","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.bsheal.2026.06.002_b0245","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.1968.03140210044011","article-title":"Low-temperature-grown RS virus in adult volunteers","volume":"204","author":"Friedewald","year":"1968","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.bsheal.2026.06.002_b0250","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/jvi.3.4.414-421.1969","article-title":"Temperature-sensitive mutants of respiratory syncytial virus","volume":"3","author":"Gharpure","year":"1969","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.bsheal.2026.06.002_b0255","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0264-410X(93)90290-E","article-title":"Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers","volume":"11","author":"Pringle","year":"1993","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0260","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1542\/peds.52.1.56","article-title":"Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children","volume":"52","author":"Kim","year":"1973","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0265","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1128\/iai.37.1.397-400.1982","article-title":"Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children","volume":"37","author":"Wright","year":"1982","journal-title":"Infect. Immun."},{"issue":"5","key":"10.1016\/j.bsheal.2026.06.002_b0270","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1542\/peds.48.5.745","article-title":"Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus","volume":"48","author":"Kim","year":"1971","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.bsheal.2026.06.002_b0275","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1006\/viro.1995.1178","article-title":"Attenuated strain of human respiratory syncytial virus contains mutations in the F-genes and L-genes","volume":"208","author":"Connors","year":"1995","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.bsheal.2026.06.002_b0280","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0264-410X(94)00074-W","article-title":"Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization","volume":"13","author":"Crowe","year":"1995","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.bsheal.2026.06.002_b0285","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/JVI.73.2.871-877.1999","article-title":"Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530\/1030 to RSV vaccine candidate cpts248\/404 increases its attenuation and temperature sensitivity","volume":"73","author":"Whitehead","year":"1999","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.bsheal.2026.06.002_b0290","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1006\/viro.1998.9248","article-title":"A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248\/404 is the major determinant of the temperature-sensitive and attenuation phenotypes","volume":"247","author":"Whitehead","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.bsheal.2026.06.002_b0295","doi-asserted-by":"crossref","unstructured":"R.A. Karron, Buchholz, U.J. Buchholz, P.L. Collins, Live-Attenuated Respiratory Syncytial Virus Vaccines, in: L.J. Anderson, B.S. Graham (Ed.), Challenges and Opportunities for Respiratory Syncytial Virus Vaccines, Springer, Heidelberg, 2013, pp. 259\u2013284, https:\/\/doi.org\/10.1007\/978-3-642-38919-1_13.","DOI":"10.1007\/978-3-642-38919-1_13"},{"issue":"4","key":"10.1016\/j.bsheal.2026.06.002_b0300","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/infdis\/173.4.829","article-title":"Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates","volume":"173","author":"Crowe","year":"1996","journal-title":"J. Infect. Dis."},{"issue":"25","key":"10.1016\/j.bsheal.2026.06.002_b0305","doi-asserted-by":"crossref","first-page":"13961","DOI":"10.1073\/pnas.94.25.13961","article-title":"Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant","volume":"94","author":"Karron","year":"1997","journal-title":"PNAS"},{"issue":"41","key":"10.1016\/j.bsheal.2026.06.002_b0310","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1016\/j.vaccine.2009.07.022","article-title":"Codon stabilization analysis of the \u201c248\u201d temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates","volume":"27","author":"Luongo","year":"2009","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.bsheal.2026.06.002_b0315","doi-asserted-by":"crossref","first-page":"10792","DOI":"10.1128\/JVI.01227-12","article-title":"Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics","volume":"86","author":"Luongo","year":"2012","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0320","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virusres.2005.06.013","article-title":"Genetic stability determinants of temperature sensitive, live attenuated respiratory syncytial virus vaccine candidates","volume":"115","author":"Lin","year":"2006","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0325","first-page":"1","article-title":"Live virus vaccines against human respiratory syncytial virus [in Chinese]","volume":"41","author":"He","year":"2011","journal-title":"Sci. Sinica Vitae"},{"issue":"18","key":"10.1016\/j.bsheal.2026.06.002_b0330","doi-asserted-by":"crossref","first-page":"8234","DOI":"10.1128\/JVI.74.18.8234-8242.2000","article-title":"Bovine respiratory syncytial virus nonstructural proteins NS1 and NS2 cooperatively antagonize alpha\/beta interferon-induced antiviral response","volume":"74","author":"Schlender","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.bsheal.2026.06.002_b0335","doi-asserted-by":"crossref","unstructured":"M.N. Teng, S.S. Whitehead, A. Bermingham, M. St Claire, W.R. Elkins, B.R. Murphy, P.L. Collins, Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees, J. Virol. 74(19) (2000) 9317\u20139321, https:\/\/doi.org\/10.1128\/jvi.74.19.9317-9321.2000.","DOI":"10.1128\/JVI.74.19.9317-9321.2000"},{"issue":"11","key":"10.1016\/j.bsheal.2026.06.002_b0340","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1128\/JVI.78.11.5773-5783.2004","article-title":"Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro","volume":"78","author":"Elliott","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.bsheal.2026.06.002_b0345","doi-asserted-by":"crossref","unstructured":"M.K. Roe, M.A. Perez, H.M. Hsiao, S.A. Lapp, H.Y. Sun, S. Jadhao, A.R. Young, Y.S. Batista, R.C. Reed, A. Taz, et al., An RSV live-attenuated vaccine candidate lacking G protein mucin domains is attenuated, immunogenic, and effective in preventing RSV in BALB\/c mice, J. Infect. Dis. 227 (1) (2022) 50\u201360, https:\/\/doi.org\/10.1093\/infdis\/jiac382.","DOI":"10.1093\/infdis\/jiac382"},{"key":"10.1016\/j.bsheal.2026.06.002_b0350","doi-asserted-by":"crossref","unstructured":"S.S. Whitehead, A. Bukreyev, M.N. Teng, C.Y. Firestone, M. St Claire, W.R. Elkins, P.L. Collins, B.R. Murphy, Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees, J. Virol. 73 (4) (1999) 3438\u20133442, https:\/\/doi.org\/10.1128\/jvi.73.4.3438-3442.1999.","DOI":"10.1128\/JVI.73.4.3438-3442.1999"},{"issue":"5","key":"10.1016\/j.bsheal.2026.06.002_b0355","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1164\/rccm.202005-1660OC","article-title":"Live-attenuated vaccines prevent respiratory syncytial virus-associated illness in young children","volume":"203","author":"Karron","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0360","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/infdis\/jiz408","article-title":"Safety and immunogenicity of the respiratory syncytial virus vaccine RSV\/DeltaNS2\/Delta1313\/I1314L in RSV-seronegative children","volume":"222","author":"Karron","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.bsheal.2026.06.002_b0365","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/infdis\/jiac253","article-title":"International maternal pediatric adolescent, evaluation of recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV\/DeltaNS2\/Delta1313\/I1314L and RSV\/276 in RSV-seronegative children","volume":"226","author":"Cunningham","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bsheal.2026.06.002_b0370","doi-asserted-by":"crossref","unstructured":"R.A. Karron, C. Luongo, B. Thumar, K.M. Loehr, J.A. Englund, P.L. Collins, U.J. Buchholz, A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children, Sci. Transl. Med. 7(312) (2015) 312ra175, https:\/\/doi.org\/10.1126\/scitranslmed.aac8463.","DOI":"10.1126\/scitranslmed.aac8463"},{"issue":"4","key":"10.1016\/j.bsheal.2026.06.002_b0375","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1128\/JVI.02769-12","article-title":"Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature","volume":"87","author":"Luongo","year":"2013","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.bsheal.2026.06.002_b0380","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1128\/JVI.78.12.6705.2004","article-title":"Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages","volume":"78","author":"Spann","year":"2004","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.bsheal.2026.06.002_b0385","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1128\/JVI.01420-06","article-title":"Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-kappaB-dependent, interferon-independent mechanism and facilitate virus growth","volume":"81","author":"Bitko","year":"2007","journal-title":"J. Virol."},{"issue":"15","key":"10.1016\/j.bsheal.2026.06.002_b0390","doi-asserted-by":"crossref","first-page":"8426","DOI":"10.1128\/JVI.77.15.8426-8439.2003","article-title":"Role of alpha\/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins","volume":"77","author":"Valarcher","year":"2003","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.bsheal.2026.06.002_b0395","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1172\/JCI72948","article-title":"RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction","volume":"124","author":"Liesman","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"20","key":"10.1016\/j.bsheal.2026.06.002_b0400","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1073\/pnas.96.20.11259","article-title":"The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription","volume":"96","author":"Bermingham","year":"1999","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0405","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1128\/JVI.74.1.74-82.2000","article-title":"Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents","volume":"74","author":"Jin","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.bsheal.2026.06.002_b0410","doi-asserted-by":"crossref","first-page":"13916","DOI":"10.1038\/ncomms13916","article-title":"A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation","volume":"7","author":"Stobart","year":"2016","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.bsheal.2026.06.002_b0415","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1016\/j.vaccine.2020.02.056","article-title":"A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates","volume":"38","author":"Mueller","year":"2020","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0420","doi-asserted-by":"crossref","first-page":"E386","DOI":"10.1073\/pnas.1619242114","article-title":"Genetic stability of genome-scale deoptimized RNA virus vaccine candidates under selective pressure","volume":"114","author":"Le Nouen","year":"2017","journal-title":"PNAS"},{"key":"10.1016\/j.bsheal.2026.06.002_b0425","doi-asserted-by":"crossref","unstructured":"J. Schon, G.T. Barut, B.S. Trueb, N.J. Halwe, I. Berenguer Veiga, A. Kratzel, L. Ulrich, J.N. Kelly, M. Brugger, C. Wylezich, et al., A safe, effective and adaptable live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome modifications, Nat. Microbiol. 9 (8) (2024) 2099-2112, https:\/\/doi.org\/10.1038\/s41564-024-01755-1.","DOI":"10.1038\/s41564-024-01755-1"},{"issue":"8","key":"10.1016\/j.bsheal.2026.06.002_b0430","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41564-024-01770-2","article-title":"The evolving landscape of live attenuated COVID-19 vaccines","volume":"9","author":"Pecetta","year":"2024","journal-title":"Nat. Microbiol."},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0435","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jviromet.2006.11.024","article-title":"An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials","volume":"141","author":"Surman","year":"2007","journal-title":"J. Virol. Methods"},{"issue":"9","key":"10.1016\/j.bsheal.2026.06.002_b0440","doi-asserted-by":"crossref","first-page":"582","DOI":"10.4161\/hv.9131","article-title":"Challenges in developing a pediatric RSV vaccine","volume":"5","author":"Schickli","year":"2009","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.bsheal.2026.06.002_b0445","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3389\/fimmu.2019.01006","article-title":"Prevention of pediatric respiratory syncytial virus lower respiratory tract illness: perspectives for the next decade","volume":"10","author":"Aranda","year":"2019","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.bsheal.2026.06.002_b0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077104","article-title":"Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age","volume":"8","author":"Malkin","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.bsheal.2026.06.002_b0455","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/infdis\/jiy040","article-title":"International maternal pediatric adolescent, live-attenuated respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is highly immunogenic in Children","volume":"217","author":"McFarland","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.bsheal.2026.06.002_b0460","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/infdis\/jiz603","article-title":"Live respiratory syncytial virus attenuated by m2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children","volume":"221","author":"McFarland","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.bsheal.2026.06.002_b0465","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/infdis\/jiy066","article-title":"Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in rsv-seronegative infants and children","volume":"217","author":"Buchholz","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.bsheal.2026.06.002_b0470","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1093\/infdis\/jiaa049","article-title":"Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with small hydrophobic noncoding region is highly immunogenic in children","volume":"221","author":"McFarland","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.bsheal.2026.06.002_b0475","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz212","article-title":"Live-attenuated respiratory syncytial virus vaccine with deletion of RNA synthesis regulatory protein M2-2 and cold passage mutations is overattenuated","volume":"6","author":"Cunningham","year":"2019","journal-title":"Open Forum Infect. Dis."},{"issue":"12","key":"10.1016\/j.bsheal.2026.06.002_b0480","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae679","article-title":"Study, infectivity and immunogenicity of live-attenuated respiratory syncytial virus vaccines in human immunodeficiency virus-exposed uninfected children","volume":"11","author":"Kelly","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.bsheal.2026.06.002_b0485","doi-asserted-by":"crossref","unstructured":"R. Dagan, L.L. Hammitt, B. Seoane Nunez, M. Baca Cots, M. Bosheva, S.A. Madhi, W.J. Muller, H.J. Zar, Y. Chang, et al., Infants receiving a single dose of nirsevimab to prevent RSV do not have evidence of enhanced disease in their second RSV season, J Pediatric. Infect. Dis. Soc. 13 (2) (2024) 144-147, https:\/\/doi.org\/10.1093\/jpids\/piad113.","DOI":"10.1093\/jpids\/piad113"},{"issue":"7","key":"10.1016\/j.bsheal.2026.06.002_b0490","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.4049\/jimmunol.167.7.3910","article-title":"Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines","volume":"167","author":"Crowe","year":"2001","journal-title":"J. Immunol."},{"issue":"6553","key":"10.1016\/j.bsheal.2026.06.002_b0495","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1126\/science.abg9857","article-title":"Scent of a vaccine","volume":"373","author":"Lund","year":"2021","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bsheal.2026.06.002_b0500","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/cid\/ciae460","article-title":"Vaccine development should be polytheistic, not monotheistic","volume":"79","author":"Plotkin","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bsheal.2026.06.002_b0505","doi-asserted-by":"crossref","unstructured":"M. Madhavan, A.J. Ritchie, J. Aboagye, D. Jenkin, S. Provstgaad-Morys, I. Tarbet, D. Woods, S. Davies, M. Baker, A. Platt, et al., Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: an open-label partially-randomised ascending dose phase I trial, EBioMedicine 85 (2022) 104298, https:\/\/doi.org\/10.1016\/j.ebiom.2022.104298.","DOI":"10.1016\/j.ebiom.2022.104298"},{"key":"10.1016\/j.bsheal.2026.06.002_b0510","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(22)00291-2","article-title":"Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape","volume":"23","author":"Mazur","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"9","key":"10.1016\/j.bsheal.2026.06.002_b0515","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500026","article-title":"Live-attenuated intranasal RSV vaccine in infants and toddlers","volume":"4","author":"Idoko","year":"2025","journal-title":"NEJM Evid."},{"issue":"10","key":"10.1016\/j.bsheal.2026.06.002_b0520","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005133","article-title":"Retrospective parameter estimation and forecast of respiratory syncytial virus in the United States","volume":"12","author":"Reis","year":"2016","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.bsheal.2026.06.002_b0525","first-page":"23","article-title":"Simulation of four respiratory viruses and inference of epidemiological parameters","volume":"3","author":"Reis","year":"2018","journal-title":"Infect. Dis. Model"},{"issue":"24","key":"10.1016\/j.bsheal.2026.06.002_b0530","doi-asserted-by":"crossref","first-page":"12128","DOI":"10.1128\/JVI.75.24.12128-12140.2001","article-title":"Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells","volume":"75","author":"Bukreyev","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.bsheal.2026.06.002_b0535","unstructured":"Sanofi, Study of an live-attenuated respiratory syncytial virus vaccine in infants and toddlers (VAD00001). https:\/\/clinicaltrials.gov\/study\/NCT04491877?term=NCT04491877&viewType=Card&rank=1, 2025 (accessed 23 July 2025)."},{"key":"10.1016\/j.bsheal.2026.06.002_b0540","doi-asserted-by":"crossref","unstructured":"R.A. Karron, C. Luongo, S. Woods, J. Oliva, P.L. Collins, U.J. Buchholz, C. Council-Dibitetto, M. Gatto, T. Ghasri, A. Gormley, et al., Evaluation of the live-attenuated intranasal respiratory syncytial virus (RSV) vaccine RSV\/6120\/DeltaNS2\/1030s in RSV-seronegative young children, J. Infect. Dis. 229 (2) (2024) 346-354, https:\/\/doi.org\/10.1093\/infdis\/jiad281.","DOI":"10.1093\/infdis\/jiad281"},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0545","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1006\/viro.2000.0393","article-title":"Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo","volume":"273","author":"Jin","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.bsheal.2026.06.002_b0550","doi-asserted-by":"crossref","first-page":"1829916","DOI":"10.3389\/fimmu.2026.1829916","article-title":"Evaluation of a strain Long human respiratory syncytial virus with M2\u20132 gene deletion in intranasally vaccinated BALB\/c mice","volume":"17","author":"Shu","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bsheal.2026.06.002_b0555","unstructured":"IMPAACT2021, Randomized phase I\/II study of the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV delta NS2\/ delta 1313\/I1314L, RSV 6120\/ delta NS2\/1030s, RSV 276 or Placebo, delivered as nose drops to RSV-seronegative children 6 to 24 months of age. https:\/\/www.impaactnetwork.org\/studies\/impaact2021, 2021 (accessed 23 July 2025)."},{"issue":"5","key":"10.1016\/j.bsheal.2026.06.002_b0560","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1128\/JVI.72.5.4467-4471.1998","article-title":"Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees","volume":"72","author":"Whitehead","year":"1998","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.bsheal.2026.06.002_b0565","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3390\/pathogens12101259","article-title":"Respiratory syncytial virus vaccines: A review of the candidates and the approved vaccines","volume":"12","author":"Topalidou","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.bsheal.2026.06.002_b0570","unstructured":"NIAID, Evaluating the infectivity, safety and immunogenicity of respiratory syncytial virus vaccines, RSV 6120\/\u2206NS1 and RSV 6120\/F1\/G2\/\u2206NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children. https:\/\/clinicaltrials.gov\/study\/NCT03596801, 2026 (accessed 24 October 2025)."},{"key":"10.1016\/j.bsheal.2026.06.002_b0575","doi-asserted-by":"crossref","unstructured":"S. Schaerlaekens, L. Jacobs, K. Stobbelaar, P. Cos, P. Delputte, All eyes on the prefusion-stabilized f construct, but are we missing the potential of alternative targets for respiratory syncytial virus vaccine design? Vaccines (Basel) 12 (1) (2024) 97, https:\/\/doi.org\/10.3390\/vaccines12010097.","DOI":"10.3390\/vaccines12010097"},{"key":"10.1016\/j.bsheal.2026.06.002_b0580","unstructured":"Clinical Trials Arena, Meissa reports positive data from trial of paediatric RSV vaccine. https:\/\/www.clinicaltrialsarena.com\/news\/meissa-data-rsv-vaccine\/, 2023 (accessed 23 July 2025)."},{"key":"10.1016\/j.bsheal.2026.06.002_b0585","doi-asserted-by":"crossref","unstructured":"J. Terstappen, S.F. Hak, A. Bhan, D. Bogaert, L.J. Bont, U.J. Buchholz, A.D. Clark, C. Cohen, R. Dagan, D.R. Feikin, et al., The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access, Lancet Infect. Dis. 24 (12) (2024) e747\u2013e761, https:\/\/doi.org\/10.1016\/S1473-3099(24)00455-9.","DOI":"10.1016\/S1473-3099(24)00455-9"},{"key":"10.1016\/j.bsheal.2026.06.002_b0590","unstructured":"G. Masson, Meissa Vaccines' future in limbo due to current fundraising climate: CEO. https:\/\/www.fiercebiotech.com\/biotech\/meissa-vaccines-future-limbo-due-current-fundraising-climate-ceo, 2024 (accessed 23 July 2025)."},{"issue":"21","key":"10.1016\/j.bsheal.2026.06.002_b0595","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMcibr0805820","article-title":"Attenuation by a thousand cuts","volume":"359","author":"Coffin","year":"2008","journal-title":"NEJM"},{"issue":"36","key":"10.1016\/j.bsheal.2026.06.002_b0600","doi-asserted-by":"crossref","first-page":"13169","DOI":"10.1073\/pnas.1411290111","article-title":"Attenuation of human respiratory syncytial virus by genome-scale codon-pair deoptimization","volume":"111","author":"Le Nouen","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.bsheal.2026.06.002_b0605","doi-asserted-by":"crossref","unstructured":"M. Levy, J.W. Chen, J.A. Kaiser, H.S. Park, X. Liu, L. Yang, C. Santos, U.J. Buchholz, C. Le Nouen, Intranasal respiratory syncytial virus vaccine attenuated by codon-pair deoptimization of seven open reading frames is genetically stable and elicits mucosal and systemic immunity and protection against challenge virus replication in hamsters, PLoS Pathog. 20 (5) (2024) e1012198, https:\/\/doi.org\/10.1371\/journal.ppat.1012198.","DOI":"10.1371\/journal.ppat.1012198"},{"key":"10.1016\/j.bsheal.2026.06.002_b0610","unstructured":"Sanofi, Press Release. https:\/\/www.sanofi.com\/assets\/dotcom\/pressreleases\/2025\/2025-10-24-05-30-00-3172594-en.pdf, 2025 (accessed 24 October 2025)."},{"key":"10.1016\/j.bsheal.2026.06.002_b0615","doi-asserted-by":"crossref","unstructured":"J.V. Williams, J.H. Weitkamp, D.L. Blum, B.J. LaFleur, J.E. Crowe Jr., The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations, Mol. Immunol. 47 (2\u20133) (2009) 407\u2013414, https:\/\/doi.org\/10.1016\/j.molimm.2009.08.024.","DOI":"10.1016\/j.molimm.2009.08.024"},{"issue":"2","key":"10.1016\/j.bsheal.2026.06.002_b0620","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/viro.2002.1437","article-title":"Respiratory syncytial virus: reverse genetics and vaccine strategies","volume":"296","author":"Collins","year":"2002","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0625","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/jmv.1890010302","article-title":"Experimental respiratory syncytial virus infection of four species of primates","volume":"1","author":"Belshe","year":"1977","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bsheal.2026.06.002_b0630","doi-asserted-by":"crossref","unstructured":"J.E. Crowe Jr., P.T. Bui, W.T. London, A.R. Davis, P.P. Hung, R.M. Chanock, B.R. Murphy, Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis, Vaccine 12 (8) (1994) 691\u2013699, https:\/\/doi.org\/10.1016\/0264-410x(94)90218-6.","DOI":"10.1016\/0264-410X(94)90218-6"},{"key":"10.1016\/j.bsheal.2026.06.002_b0635","unstructured":"NEAVS, International bans. https:\/\/releasechimps.org\/laws\/international-bans, 2021 (accessed 23 July 2025)."},{"key":"10.1016\/j.bsheal.2026.06.002_b0640","unstructured":"NIH, NIH will no longer support biomedical research on chimpanzees. https:\/\/www.nih.gov\/news-events\/digital-media-kits\/chimpanzees-research, 2025 (accessed 23 July 2025)."},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0645","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/infdis\/167.3.553","article-title":"A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine","volume":"167","author":"Kakuk","year":"1993","journal-title":"J. Infect. Dis."},{"issue":"25\u201326","key":"10.1016\/j.bsheal.2026.06.002_b0650","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1016\/S0264-410X(03)00426-2","article-title":"Evaluation of recombinant respiratory syncytial virus gene deletion mutants in african green monkeys for their potential as live attenuated vaccine candidates","volume":"21","author":"Jin","year":"2003","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0655","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1128\/iai.23.3.723-728.1979","article-title":"Intramuscular inoculation of live respiratory syncytial virus induces immunity in cotton rats","volume":"23","author":"Prince","year":"1979","journal-title":"Infect. Immun."},{"issue":"11","key":"10.1016\/j.bsheal.2026.06.002_b0660","first-page":"1385","article-title":"Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus)","volume":"79","author":"Prince","year":"1999","journal-title":"Lab. Invest."},{"key":"10.1016\/j.bsheal.2026.06.002_b0665","doi-asserted-by":"crossref","unstructured":"C.A. Rostad, C.C. Stobart, B.E. Gilbert, R.J. Pickles, A.L. Hotard, J. Meng, J.C.G. Blanco, S.M. Moin, B.S. Graham, P.A. Piedra, M.L. Moore, A Recombinant respiratory syncytial virus vaccine candidate attenuated by a low-fusion F protein is immunogenic and protective against challenge in cotton rats, J. Virol. 90 (16) (2016) 7508\u20137518, http:\/\/doi.org\/10.1128\/JVI.00012-16.","DOI":"10.1128\/JVI.00012-16"},{"key":"10.1016\/j.bsheal.2026.06.002_b0670","doi-asserted-by":"crossref","unstructured":"R. Groppo, J. DiNapoli, K. Il Jeong, M. Kishko, N. Jackson, H. Kleanthous, S. Delagrave, L. Zhang, M. Parrington, Effect of genetic background and delivery route on the preclinical properties of a live attenuated RSV vaccine, PLoS One 13 (6) (2018) e0199452, https:\/\/doi.org\/10.1371\/journal.pone.0199452.","DOI":"10.1371\/journal.pone.0199452"},{"key":"10.1016\/j.bsheal.2026.06.002_b0675","doi-asserted-by":"crossref","unstructured":"J. Alamares-Sapuay, M. Kishko, C. Lai, M. Parrington, S. Delagrave, R. Herbert, A. Castens, J. Swerczek, C. Luongo, L. Yang, et al., Mutations in the F protein of the live-attenuated respiratory syncytial virus vaccine candidate DeltaNS2\/Delta1313\/I1314L increase the stability of infectivity and content of prefusion F protein, PLoS One 19 (4) (2024) e0301773, https:\/\/doi.org\/10.1371\/journal.pone.0301773.","DOI":"10.1371\/journal.pone.0301773"},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0680","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.vaccine.2016.11.054","article-title":"Animal models of respiratory syncytial virus infection","volume":"35","author":"Taylor","year":"2017","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.bsheal.2026.06.002_b0685","doi-asserted-by":"crossref","first-page":"8651","DOI":"10.1128\/JVI.79.13.8651-8654.2005","article-title":"Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract","volume":"79","author":"Wright","year":"2005","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.bsheal.2026.06.002_b0690","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005318","article-title":"Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures","volume":"11","author":"Johnson","year":"2015","journal-title":"PLoS Pathog."},{"issue":"9","key":"10.1016\/j.bsheal.2026.06.002_b0695","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1099\/vir.0.000218","article-title":"CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells","volume":"96","author":"Chirkova","year":"2015","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.bsheal.2026.06.002_b0700","doi-asserted-by":"crossref","unstructured":"K.I. Jeong, P.A. Piepenhagen, M. Kishko, J.M. DiNapoli, R.P. Groppo, L. Zhang, J. Almond, H. Kleanthous, S. Delagrave, M. Parrington, CX3CR1 Is expressed in differentiated human ciliated airway cells and co-localizes with respiratory syncytial virus on cilia in a g protein-dependent manner, PLoS One 10 (6) (2015) e0130517, https:\/\/doi.org\/10.1371\/journal.pone.0130517.","DOI":"10.1371\/journal.pone.0130517"},{"key":"10.1016\/j.bsheal.2026.06.002_b0705","doi-asserted-by":"crossref","unstructured":"B. Ying, K. Pyles, T.L. Darling, K. Seehra, T. Pham, L.C. Huang, H.H. Harastani, A. Sharma, P. Desai, E.A. Kashentseva, et al., An intranasal adenoviral-vectored vaccine protects against highly pathogenic avian influenza H5N1 in naive and antigen-experienced animals, Cell Rep. Med. 7 (2) (2026) 102582, \u200bhttps:\/\/doi.org\/10.1016\/j.xcrm.2025.102582.","DOI":"10.1016\/j.xcrm.2025.102582"},{"key":"10.1016\/j.bsheal.2026.06.002_b0710","doi-asserted-by":"crossref","unstructured":"N. Te, A.W.H. Chin, H. Gu, J. Zhirong Jia, Y. Huang, S.M.S. Cheng, C. Wah Tan, J. Zhao, K. Pui Yan Hui, M. Chi Wai Chan, et al., Broad beta-CoV immunity and transmission blockade by a single-dose live-attenuated vaccine with atypical codon usage, PNAS 123(4) (2026) e2518645123, https:\/\/doi.org\/10.1073\/pnas.2518645123.","DOI":"10.1073\/pnas.2518645123"},{"key":"10.1016\/j.bsheal.2026.06.002_b0715","doi-asserted-by":"crossref","unstructured":"T. Zohar, J.C. Hsiao, N. Mehta, J. Das, A. Devadhasan, W. Karpinski, C. Callahan, M.P. Citron, D.J. DiStefano, S. Touch, et al., Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates, Cell Host Microbe 30(1) (2022) 41\u201352 e5, https:\/\/doi.org\/10.1016\/j.chom.2021.11.006.","DOI":"10.1016\/j.chom.2021.11.006"},{"key":"10.1016\/j.bsheal.2026.06.002_b0720","doi-asserted-by":"crossref","unstructured":"Y.C. Bartsch, D. Cizmeci, J. Kang, T. Zohar, S. Periasamy, N. Mehta, J. Tolboom, L. Van der Fits, J. Sadoff, C. Comeaux, et al., Antibody effector functions are associated with protection from respiratory syncytial virus, Cell 185 (26) (2022) 4873\u20134886 e10, https:\/\/doi.org\/10.1016\/j.cell.2022.11.012.","DOI":"10.1016\/j.cell.2022.11.012"},{"key":"10.1016\/j.bsheal.2026.06.002_b0725","doi-asserted-by":"crossref","unstructured":"M.S. Habibi, A. Jozwik, S. Makris, J. Dunning, A. Paras, J.P. DeVincenzo, C.A. de Haan, J. Wrammert, P.J. Openshaw, C. Chiu, I. Mechanisms of Severe Acute Influenza Consortium, Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus, Am. J. Respir. Crit. Care Med. 191 (9) (2015) 1040\u20131049, https:\/\/doi.org\/10.1164\/rccm.201412-2256OC.","DOI":"10.1164\/rccm.201412-2256OC"},{"issue":"6","key":"10.1016\/j.bsheal.2026.06.002_b0730","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/infdis\/169.6.1368","article-title":"Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin","volume":"169","author":"Siber","year":"1994","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.bsheal.2026.06.002_b0735","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1086\/421524","article-title":"Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults","volume":"190","author":"Walsh","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bsheal.2026.06.002_b0740","doi-asserted-by":"crossref","unstructured":"A. Jozwik, M.S. Habibi, A. Paras, J. Zhu, A. Guvenel, J. Dhariwal, M. Almond, E.H.C. Wong, A. Sykes, M. Maybeno, et al., RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection, Nat. Commun. 6 (2015) 10224, https:\/\/doi.org\/10.1038\/ncomms10224.","DOI":"10.1038\/ncomms10224"},{"key":"10.1016\/j.bsheal.2026.06.002_b0745","doi-asserted-by":"crossref","first-page":"920256","DOI":"10.3389\/fimmu.2022.920256","article-title":"Mucosal immunization with an adenoviral vector vaccine confers superior protection against RSV compared to natural immunity","volume":"13","author":"Maier","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bsheal.2026.06.002_b0750","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM198607103150201","article-title":"Respiratory syncytial viral infection in children with compromised immune function","volume":"315","author":"Hall","year":"1986","journal-title":"NEJM"},{"key":"10.1016\/j.bsheal.2026.06.002_b0755","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3389\/fimmu.2018.00678","article-title":"The CD8 T cell response to respiratory virus infections","volume":"9","author":"Schmidt","year":"2018","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.bsheal.2026.06.002_b0760","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/318815","article-title":"HLA-restricted CD8+ cytotoxic T lymphocyte, interferon-gamma, and interleukin-4 responses to respiratory syncytial virus infection in infants and children","volume":"183","author":"Mbawuike","year":"2001","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.bsheal.2026.06.002_b0765","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0022-3476(80)80799-2","article-title":"Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity","volume":"96","author":"Fishaut","year":"1980","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0770","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2249.1992.tb06482.x","article-title":"CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells","volume":"88","author":"Alwan","year":"1992","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0775","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006810","article-title":"Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection","volume":"14","author":"Schmidt","year":"2018","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0780","first-page":"133","article-title":"Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells","volume":"62","author":"Cannon","year":"1987","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0785","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1084\/jem.168.3.1163","article-title":"Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus","volume":"168","author":"Cannon","year":"1988","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0790","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1172\/JCI115362","article-title":"Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice","volume":"88","author":"Graham","year":"1991","journal-title":"J. Clin. Invest."},{"issue":"16","key":"10.1016\/j.bsheal.2026.06.002_b0795","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1073\/pnas.1402458111","article-title":"Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy","volume":"111","author":"Hiatt","year":"2014","journal-title":"PNAS"},{"issue":"6","key":"10.1016\/j.bsheal.2026.06.002_b0800","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0264-410X(95)00222-M","article-title":"Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2","volume":"14","author":"Corbeil","year":"1996","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0805","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1542\/peds.2006-2836","article-title":"Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children","volume":"120","author":"Piedra","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.bsheal.2026.06.002_b0810","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fmicb.2018.00083","article-title":"Non-specific effect of vaccines: Immediate protection against respiratory syncytial virus infection by a live attenuated influenza vaccine","volume":"9","author":"Lee","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.bsheal.2026.06.002_b0815","doi-asserted-by":"crossref","DOI":"10.1126\/science.aea1260","article-title":"Mucosal vaccination in mice provides protection from diverse respiratory threats","volume":"392","author":"Zhang","year":"2026","journal-title":"Science"},{"key":"10.1016\/j.bsheal.2026.06.002_b0820","doi-asserted-by":"crossref","unstructured":"D.M. Murphy, D.J. Cox, S.A. Connolly, E.P. Breen, A.A. Brugman, J.J. Phelan, J. Keane, S.A. Basdeo, Trained immunity is induced in humans after immunization with an adenoviral vector COVID-19 vaccine, J. Clin. Invest. 133 (2) (2023) e162581, https:\/\/doi.org\/10.1172\/JCI162581.","DOI":"10.1172\/JCI162581"},{"key":"10.1016\/j.bsheal.2026.06.002_b0825","doi-asserted-by":"crossref","unstructured":"D.I. Kwon, S.H. Bhagchandani, S.A. Ehrenzeller, A. Iwasaki, Harnessing mucosal immunity for protective vaccines, Nat. Rev. Immunol. 26 (2026) 507\u2013524, https:\/\/doi.org\/10.1038\/s41577-026-01273-7.","DOI":"10.1038\/s41577-026-01273-7"},{"issue":"5","key":"10.1016\/j.bsheal.2026.06.002_b0830","doi-asserted-by":"crossref","first-page":"gae183","DOI":"10.1093\/pnasnexus\/pgae183","article-title":"Intranasal influenza-vectored COVID-19 vaccines confer broad protection against SARS-CoV-2 XBB variants in hamsters","volume":"3","author":"Chen","year":"2024","journal-title":"PNAS Nexus"},{"issue":"13","key":"10.1016\/j.bsheal.2026.06.002_b0835","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.scib.2022.05.018","article-title":"A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2","volume":"67","author":"Chen","year":"2022","journal-title":"Sci. Bull. (Beijing)"},{"key":"10.1016\/j.bsheal.2026.06.002_b0840","doi-asserted-by":"crossref","unstructured":"F. Dotiwala, A.K. Upadhyay, Next generation mucosal vaccine strategy for respiratory pathogens, Vaccines (Basel) 11(10) (2023) 1585, https:\/\/doi.org\/10.3390\/vaccines11101585.","DOI":"10.3390\/vaccines11101585"},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0845","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41541-023-00717-8","article-title":"Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin\u00ae)","volume":"8","author":"Singh","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.bsheal.2026.06.002_b0850","doi-asserted-by":"crossref","first-page":"1063679","DOI":"10.3389\/fimmu.2022.1063679","article-title":"Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)","volume":"13","author":"Sunagar","year":"2022","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.bsheal.2026.06.002_b0855","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S2213-2600(23)00349-1","article-title":"Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Zhu","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0860","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/21645515.2017.1377376","article-title":"Immune responses after live attenuated influenza vaccination","volume":"14","author":"Mohn","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.bsheal.2026.06.002_b0865","doi-asserted-by":"crossref","unstructured":"K.S.R. Pebody, K. Subbarao, Influenza vaccine-live, in W. Orenstein, P. Offit, K. M. Edwards, S. Plotkin (Eds.), Plotkin's vaccines, Elsevier Inc., 2023, pp. 552\u2013576.e8.","DOI":"10.1016\/B978-0-323-79058-1.00034-7"},{"key":"10.1016\/j.bsheal.2026.06.002_b0870","doi-asserted-by":"crossref","unstructured":"P.F. Wright, A.G. Hoen, N.A. Ilyushina, E.P. Brown, M.E. Ackerman, W. Wieland-Alter, R.I. Connor, S. Jegaskanda, Y. Rosenberg-Hasson, B.C. Haynes, C.J. Luke, K. Subbarao, J.J. Treanor, Correlates of immunity to influenza as determined by challenge of children with live, attenuated influenza vaccine, Open Forum Infect. Dis. 3 (2) (2016) ofw108, https:\/\/doi.org\/10.1093\/ofid\/ofw108.","DOI":"10.1093\/ofid\/ofw108"},{"issue":"9","key":"10.1016\/j.bsheal.2026.06.002_b0875","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1128\/JVI.79.9.5507-5515.2005","article-title":"Inhibition of toll-like receptor 7- and 9-mediated alpha\/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus","volume":"79","author":"Schlender","year":"2005","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0880","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0162-3109(00)00233-2","article-title":"Immune-mediated disease pathogenesis in respiratory syncytial virus infection","volume":"48","author":"Graham","year":"2000","journal-title":"Immunopharmacology"},{"issue":"2","key":"10.1016\/j.bsheal.2026.06.002_b0885","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.pharmthera.2006.04.008","article-title":"Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics","volume":"112","author":"Moore","year":"2006","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.bsheal.2026.06.002_b0890","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s12250-021-00345-3","article-title":"Evaluation of the safety and immune efficacy of recombinant human respiratory syncytial virus strain long live attenuated vaccine candidates","volume":"36","author":"Wang","year":"2021","journal-title":"Virol. Sin."},{"key":"10.1016\/j.bsheal.2026.06.002_b0895","doi-asserted-by":"crossref","first-page":"1084139","DOI":"10.3389\/fimmu.2022.1084139","article-title":"Immune escaping of the novel genotypes of human respiratory syncytial virus based on gene sequence variation","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0900","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/QCO.0000000000000917","article-title":"Respiratory syncytial virus infection in the modern era","volume":"36","author":"Ludlow","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.bsheal.2026.06.002_b0905","doi-asserted-by":"crossref","first-page":"e01939-20","DOI":"10.1128\/JVI.01939-20","article-title":"Nonsegmented negative-sense RNA viruses utilize N6-methyladenosine (m(6)A) as a common strategy to evade host innate immunity","volume":"95","author":"Lu","year":"2021","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.bsheal.2026.06.002_b0910","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41564-019-0653-9","article-title":"N(6)-methyladenosine modification enables viral RNA to escape recognition by RNA sensor RIG-I","volume":"5","author":"Lu","year":"2020","journal-title":"Nat. Microbiol."},{"issue":"12","key":"10.1016\/j.bsheal.2026.06.002_b0915","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010142","article-title":"Viral RNA N6-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus","volume":"17","author":"Xue","year":"2021","journal-title":"PLoS Pathog."},{"issue":"Pt 12","key":"10.1016\/j.bsheal.2026.06.002_b0920","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1099\/vir.0.055368-0","article-title":"A single amino acid in the F2 subunit of respiratory syncytial virus fusion protein alters growth and fusogenicity","volume":"94","author":"Lawlor","year":"2013","journal-title":"J. Gen. Virol."},{"issue":"24","key":"10.1016\/j.bsheal.2026.06.002_b0925","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01831-20","article-title":"Stable attenuation of human respiratory syncytial virus for live vaccines by deletion and insertion of amino acids in the hinge region between the mRNA capping and methyltransferase domains of the large polymerase protein","volume":"94","author":"Xue","year":"2020","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.bsheal.2026.06.002_b0930","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1128\/JVI.01853-08","article-title":"A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction","volume":"83","author":"Moore","year":"2009","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0935","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41541-024-00899-9","article-title":"Mucosal bivalent live attenuated vaccine protects against human metapneumovirus and respiratory syncytial virus in mice","volume":"9","author":"Ogonczyk-Makowska","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"2","key":"10.1016\/j.bsheal.2026.06.002_b0940","doi-asserted-by":"crossref","first-page":"e01512","DOI":"10.1128\/JVI.01512-20","article-title":"A parainfluenza virus vector expressing the respiratory syncytial virus (RSV) prefusion F protein is more effective than rsv for boosting a primary immunization with RSV","volume":"95","author":"Liang","year":"2020","journal-title":"J. Virol."},{"issue":"43","key":"10.1016\/j.bsheal.2026.06.002_b0945","doi-asserted-by":"crossref","first-page":"eadj7611","DOI":"10.1126\/sciadv.adj7611","article-title":"Intranasal parainfluenza virus type 5 (PIV5)-vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study","volume":"9","author":"Spearman","year":"2023","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.bsheal.2026.06.002_b0950","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/vaccines9020156","article-title":"Chimeric Measles Virus (MV\/RSV), Having ectodomains of respiratory syncytial virus (RSV) F and G proteins instead of measles envelope proteins, induced protective antibodies against RSV","volume":"9","author":"Sawada","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"10.1016\/j.bsheal.2026.06.002_b0955","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/163.4.693","article-title":"Immunity to and frequency of reinfection with respiratory syncytial virus","volume":"163","author":"Hall","year":"1991","journal-title":"J. Infect. Dis."},{"issue":"6136","key":"10.1016\/j.bsheal.2026.06.002_b0960","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bsheal.2026.06.002_b0965","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/infdis\/jiq100","article-title":"Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and\/or motavizumab","volume":"203","author":"Zhu","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bsheal.2026.06.002_b0970","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1128\/jvi.00531-25","article-title":"Evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera","volume":"99","author":"Simonich","year":"2025","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.bsheal.2026.06.002_b0975","doi-asserted-by":"crossref","first-page":"e4400","DOI":"10.1093\/cid\/ciaa951","article-title":"Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants","volume":"73","author":"Simoes","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.bsheal.2026.06.002_b0980","doi-asserted-by":"crossref","first-page":"e4409","DOI":"10.1093\/cid\/ciaa944","article-title":"How Viral Sequence Analysis May Guide Development of Respiratory Syncytial Virus Monoclonal Antibodies","volume":"73","author":"Langedijk","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0985","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1038\/s41467-023-40057-8","article-title":"Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials","volume":"14","author":"Ahani","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b0990","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1038\/s41467-021-25265-4","article-title":"Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus","volume":"12","author":"Lin","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b0995","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(24)00570-X","article-title":"Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study","volume":"25","author":"Fourati","year":"2025","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.bsheal.2026.06.002_b1000","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/infdis\/jiy189","article-title":"Prevalence and significance of substitutions in the fusion protein of respiratory syncytial virus resulting in neutralization escape from antibody MEDI8897","volume":"218","author":"Zhu","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"10098","key":"10.1016\/j.bsheal.2026.06.002_b1005","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"issue":"9725","key":"10.1016\/j.bsheal.2026.06.002_b1010","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b1015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13052-025-01844-9","article-title":"Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection","volume":"51","author":"Manti","year":"2025","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.bsheal.2026.06.002_b1020","unstructured":"Sanofi, Nirsevimab international recommendation. https:\/\/www.campus.sanofi\/ae\/products\/beyfortus\/international-recommendation, 2025 (accessed 23 July 2025)."},{"issue":"3","key":"10.1016\/j.bsheal.2026.06.002_b1025","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/atm.atm_69_24","article-title":"Saudi Initiative of Bronchiolitis Diagnosis, Management, and Prevention 2024 updated consensus on the prevention of respiratory syncytial virus","volume":"19","author":"Alharbi","year":"2024","journal-title":"Ann. Thorac. Med."},{"issue":"1","key":"10.1016\/j.bsheal.2026.06.002_b1030","doi-asserted-by":"crossref","first-page":"2506288","DOI":"10.1080\/21645515.2025.2506288","article-title":"Cost-effectiveness analysis of nirsevimab for prevention of respiratory syncytial virus disease among infants in Shanghai, China: A modeling study","volume":"21","author":"Wang","year":"2025","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["Biosafety and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590053626000893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590053626000893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:17:45Z","timestamp":1787685465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590053626000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":206,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2590053626000893"],"URL":"https:\/\/doi.org\/10.1016\/j.bsheal.2026.06.002","relation":{},"ISSN":["2590-0536"],"issn-type":[{"value":"2590-0536","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Live-attenuated vaccines of human respiratory syncytial virus for infants and young children: Progress and prospects of an old yet promising platform","name":"articletitle","label":"Article Title"},{"value":"Biosafety and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bsheal.2026.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Chinese Medical Association Publishing House Co. Ltd. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}